{"doi":"10.1128/aac.01605-15","title":"Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria","abstract":"<jats:title>ABSTRACT</jats:title><jats:p>Artemether-lumefantrine is a first-line regimen for the treatment of uncomplicated malaria during the second and third trimesters of pregnancy. Previous studies have reported changes in the pharmacokinetics and clinical outcomes following treatment with artemether-lumefantrine in pregnant women compared to nonpregnant adults; however, the results are inconclusive. We conducted a study in rural Uganda to compare the pharmacokinetics of artemether-lumefantrine and the treatment responses between 30 pregnant women and 30 nonpregnant adults with uncomplicated<jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Plasmodium falciparum</jats:named-content>malaria. All participants were uninfected with HIV, treated with a six-dose regimen of artemether-lumefantrine, and monitored clinically for 42 days. The pharmacokinetics of artemether, its metabolite dihydroartemisinin, and lumefantrine were evaluated for 21 days following treatment. We found no significant differences in the overall pharmacokinetics of artemether, dihydroartemisinin, or lumefantrine in a direct comparison of pregnant women to nonpregnant adults, except for a statistically significant but small difference in the terminal elimination half-lives of both dihydroartemisinin and lumefantrine. There were seven PCR-confirmed reinfections (5 pregnant and 2 nonpregnant participants). The observation of a shorter terminal half-life for lumefantrine may have contributed to a higher frequency of reinfection or a shorter posttreatment prophylactic period in pregnant women than in nonpregnant adults. While the comparable overall pharmacokinetic exposure is reassuring, studies are needed to further optimize antimalarial efficacy in pregnant women, particularly in high-transmission settings and because of emerging drug resistance. (This study is registered at ClinicalTrials.gov under registration no. NCT01717885.)</jats:p>","journal":"Antimicrobial Agents and Chemotherapy","year":2016,"id":658876,"datarank":0.519860385419959,"base_score":3.4657359027997265,"endowment":3.4657359027997265,"self_citation_contribution":0.519860385419959,"citation_network_contribution":0.0,"self_endowment_contribution":0.519860385419959,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":31,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1719993,"name":"Vy K. Nguyen","orcid":null,"position":1,"is_corresponding":false},{"id":367277,"name":"Richard Kajubi","orcid":"0000-0002-9179-9182","position":2,"is_corresponding":false},{"id":407221,"name":"Liusheng Huang","orcid":"0000-0003-2702-4486","position":3,"is_corresponding":false},{"id":1719994,"name":"Joshua Ssebuliba","orcid":null,"position":4,"is_corresponding":false},{"id":1719995,"name":"Sylvia Kiconco","orcid":null,"position":5,"is_corresponding":false},{"id":455960,"name":"Moses W. Mwima","orcid":null,"position":6,"is_corresponding":false},{"id":475616,"name":"Jane Achan","orcid":"0000-0001-8111-025X","position":7,"is_corresponding":false},{"id":407222,"name":"Francesca Aweeka","orcid":"0000-0002-6005-6124","position":8,"is_corresponding":false},{"id":134696,"name":"Sunil Parikh","orcid":null,"position":9,"is_corresponding":false},{"id":427406,"name":"Norah Mwebaza","orcid":null,"position":10,"is_corresponding":false},{"id":290871,"name":"Myaing M. Nyunt","orcid":"0000-0003-1460-0448","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria","abstract":"<jats:title>ABSTRACT</jats:title><jats:p>Artemether-lumefantrine is a first-line regimen for the treatment of uncomplicated malaria during the second and third trimesters of pregnancy. Previous studies have reported changes in the pharmacokinetics and clinical outcomes following treatment with artemether-lumefantrine in pregnant women compared to nonpregnant adults; however, the results are inconclusive. We conducted a study in rural Uganda to compare the pharmacokinetics of artemether-lumefantrine and the treatment responses between 30 pregnant women and 30 nonpregnant adults with uncomplicated<jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Plasmodium falciparum</jats:named-content>malaria. All participants were uninfected with HIV, treated with a six-dose regimen of artemether-lumefantrine, and monitored clinically for 42 days. The pharmacokinetics of artemether, its metabolite dihydroartemisinin, and lumefantrine were evaluated for 21 days following treatment. We found no significant differences in the overall pharmacokinetics of artemether, dihydroartemisinin, or lumefantrine in a direct comparison of pregnant women to nonpregnant adults, except for a statistically significant but small difference in the terminal elimination half-lives of both dihydroartemisinin and lumefantrine. There were seven PCR-confirmed reinfections (5 pregnant and 2 nonpregnant participants). The observation of a shorter terminal half-life for lumefantrine may have contributed to a higher frequency of reinfection or a shorter posttreatment prophylactic period in pregnant women than in nonpregnant adults. While the comparable overall pharmacokinetic exposure is reassuring, studies are needed to further optimize antimalarial efficacy in pregnant women, particularly in high-transmission settings and because of emerging drug resistance. (This study is registered at ClinicalTrials.gov under registration no. NCT01717885.)</jats:p>","is_dataset_classified":null,"base_score":3.4657359027997265,"endowment":3.4657359027997265,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26666942","pmcid":"PMC4775973","openalex_id":"https://openalex.org/W2286471707","authors":[],"funders":[{"funder_name":"HHS | National Institutes of Health","grant_id":"RO1 HD068174","title":null},{"funder_name":"University of California, San Francisco, Clinical and Translational Sciences Institute","grant_id":"TL1 TR000144","title":null},{"funder_name":"Center for AIDS Research, University of California, San Francisco","grant_id":"P30 AI022763","title":null},{"funder_name":"NIAID NIH HHS","grant_id":"P30 AI027763","title":null},{"funder_name":"NICHD NIH HHS","grant_id":"R01HD068174","title":null},{"funder_name":"NICHD NIH HHS","grant_id":"P01 HD059454","title":null},{"funder_name":"National Institutes of Health","grant_id":"8TL1TR000144-07","title":"Clinical and Transtional Science Institute"},{"funder_name":"National Institutes of Health","grant_id":"5R01HD068174-07","title":"Optimizing ACT use for African children in the setting of HIV and malnutrition"}],"total_grants":8,"fwci":3.9416,"citation_percentile":0.93556708,"influential_citations":0,"citation_trend":[{"year":2016,"count":2},{"year":2017,"count":3},{"year":2018,"count":7},{"year":2019,"count":2},{"year":2020,"count":6},{"year":2021,"count":3},{"year":2022,"count":1},{"year":2023,"count":2},{"year":2024,"count":3},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://aac.asm.org/content/aac/60/3/1274.full.pdf","host_type":"journal"},{"url":"https://aac.asm.org/content/aac/60/3/1274.full.pdf","host_type":"publisher"},{"url":"https://journals.asm.org/doi/pdf/10.1128/AAC.01605-15","host_type":"publisher"},{"url":"https://doi.org/10.1128/aac.01605-15","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26666942","host_type":"repository"},{"url":"https://researchonline.lshtm.ac.uk/view/creators/lshja1.html>;","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4775973","host_type":"repository"},{"url":"https://escholarship.org/uc/item/6jx237x2","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC4775973","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC4775973?pdf=render","host_type":"Europe_PMC"},{"url":"https://dx.doi.org/10.60692/gcyrm-2dd13","host_type":""},{"url":"https://dx.doi.org/10.60692/vk9jk-8z636","host_type":""},{"url":"http://dx.doi.org/10.1128/AAC.01605-15","host_type":""},{"url":"https://dx.doi.org/10.1128/aac.01605-15","host_type":""},{"url":"https://escholarship.org/content/qt6jx237x2/qt6jx237x2.pdf","host_type":""},{"url":"https://doi.org/https://doi.org/10.1128/aac.01605-15","host_type":""}],"fields_of_study":["Malaria Research and Control","Computational Drug Discovery Methods","Drug-Induced Hepatotoxicity and Protection","0302 clinical medicine","03 medical and health sciences","Adolescent","Adult","Antimalarials","Artemether","Artemisinins","Cohort Studies","Drug Therapy, Combination","Ethanolamines","Female","Fluorenes","Humans","Lumefantrine","Malaria, Falciparum","Middle Aged","Pregnancy","Pregnancy Complications, Parasitic","Prospective Studies","Treatment Outcome","Uganda","Young Adult"],"mesh_terms":["Artemether","Lumefantrine","Adolescent","Adult","Antimalarials","Drug Therapy, Combination","Ethanolamines","Female","Fluorenes","Humans","Middle Aged","Pregnancy","Prospective Studies","Uganda","Cohort Studies","Pregnancy Complications, Parasitic","Malaria, Falciparum","Treatment Outcome","Artemisinins","Young Adult"],"keywords":["Artemether/lumefantrine","Lumefantrine","Pharmacokinetics","Plasmodium falciparum","Malaria","Artemether","Medicine","Pharmacology","Artemisinin","Immunology","Cohort Studies","Pregnancy","Uganda","Prospective Studies","Malaria, Falciparum","Internal medicine","Pharmacology and Pharmaceutical Sciences","Medical microbiology","Middle Aged","Artemisinins","Obstetrics","Infectious Diseases","Treatment Outcome","Dihydroartemisinin","Oncology","5.1 Pharmaceuticals","Ethanolamines","6.1 Pharmaceuticals","Parasitic","Combination","Drug Therapy, Combination","Female","Infection","Falciparum","Adult","Prenatal Exposure to Antiepileptic Drugs","Adolescent","Clinical Sciences","Clinical Trials and Supportive Activities","Antimalarial Drugs","610","Microbiology","618","Antimalarials","Young Adult","Rare Diseases","Drug Therapy","Clinical Research","Health Sciences","Humans","Regimen","Fluorenes","Biomedical and Clinical Sciences","FOS: Clinical medicine","Mechanisms of Multidrug Resistance in Cancer","Public Health, Environmental and Occupational Health","Vector-Borne Diseases","Pregnancy Complications","Good Health and Well Being","Pregnancy Complications, Parasitic","Pediatrics, Perinatology and Child Health","Women's Health","Sexually Transmitted Infections"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":8,"sdg_label":"8. Economic growth"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-12T05:38:06.421426Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}